Home›Companies›Biotech & Pharma›AdvanCell

AdvanCell, Inc.

Develops targeted radiation treatments for people with cancer.

Updated Nov 10, 2026·Latest SEC filing Jul 16, 2026·Suggest an edit

About AdvanCell

AdvanCell is a private company based in Cambridge, Massachusetts, incorporated in 2026 in Delaware. It has reported $218,333,294 raised in one offering on Form D since July 2026. Its chief executive is Philina Lee.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jun 30, 2026Jul 16, 2026$218,333,294of $315.0M target41$5.3MEquity, Securities on exerciseRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on AdvanCell's Form D filed Jul 16, 2026.

PL
Philina Lee
Chief Executive Officer and director
JB
Jamil Beg
Director
Also a director at Kinaset Therapeutics.
KC
BM
WL
AA
Andrew Adamovich
Founder & Managing Director, Australia
AA
Anthony Aiudi
Director
Also an executive officer, director and promoter at Neutrolis and a director at i2O Therapeutics.

Sources

  1. SECAdvanCell, Inc. filing history
  2. CompanyAdvanCell contact
  3. CompanyAdvanCell company and management